|
Company:
|
89BIO, INC. (ETNB)
|
|
Form Type:
|
3
|
|
Filing Date:
|
3/25/2020
|
|
CIK:
|
0001785173
|
|
Address:
|
535 MISSION STREET
14TH FLOOR
|
|
City, State, Zip:
|
SAN FRANCISCO, California 94105
|
|
Telephone:
|
(415) 500-4614
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$25.33
|
Change:
-0.67 (-2.58%)
|
Trade Time:
May 28
|
Market Cap:
$349.40M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage biopharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of liver and
cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically
engineered glycoPEGylated analog of fibroblast growth factor 21 (" FGF21"), is
currently being developed for the treatment of nonalcoholic steatohepatitis
("NASH"). NASH is a severe form of nonalcoholic fatty liver disease ("NAFLD"),
characterized by inflammation and fibrosis in the liver that can progress to
cirrhosis, liver failure, hepatocellular carcinoma ("HCC") and death. There are
currently no approved products for the treatment of NASH. FGF21 is a
clinically-validated mechanism that has been shown in humans to reduce steatosis
and address cardio-metabolic dysregulation.
|
|
|
|